Evidence map›Paper›PMID 26108787›Full record

ArticleBMC research notes2015

Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice.

Christian Tanislav, Sonja Milde, Sabine Schwartzkopff, Björn Misselwitz, Nicole Sieweke, Manfred Kaps

Abstract read
In one paragraph

Article in BMC research notes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Christian TanislavDepartment of Neurology, Justus Liebig University, Klinikstrasse 33, 35392, Giessen, Germany. christian.tanislav@neuro.med.uni-giessen.de.
Sonja MildeDresden International University, Dresden, Germany. Sonja.Milde@di-uni.de.
Sabine SchwartzkopffAOK Division of the Federal State of Hesse, Eschborn, Frankfurt, Germany. sabine.schwartzkopff@he.aok.de.
Björn MisselwitzGeschäftsstelle Qualitätssicherung Hessen (GQH), Eschborn, Frankfurt, Germany. bmisselwitz@gqhnet.de.
Nicole SiewekeDepartment of Neurology, Justus Liebig University, Klinikstrasse 33, 35392, Giessen, Germany. nicole.sieweke@neuro.med.uni-giessen.de.
Manfred KapsDepartment of Neurology, Justus Liebig University, Klinikstrasse 33, 35392, Giessen, Germany. Manfred.Kaps@neuro.med.uni-giessen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhen applying information gathered from medical research to the clinical setting, it is imperative that the sample of the investigated patients be representative of the clinical population. Because of this fact, it is necessary to closely examine the sample's baseline characteristics in clinical trials.

methodsWe analysed baseline data of relevant trials investigating considerable proportions of patients with atrial fibrillation (AF) in the secondary stroke prevention: EAFT, SIFA, Active-W, BAFTA, RE-LY, AVERROES, ARISTOTLE and ROCKET AF. For comparing baseline data stroke patients with AF documented in a statutory stroke registry were considered. In a subgroup of patients (members of a large insurance) data on subsequent prescription for oral anticoagulants (oAK) were available.

resultsIn the stroke registry (n = 15,886) the mean age was higher than in the selected clinical trials (mean 77.7 versus 70-72 years). Among insurance members (n = 1,828), those with a prescription for oAK (n = 827) were older than patients recruited in clinical trials (mean 75.1 versus 70-72 years). Results also showed that the male sex was overrepresented in clinical trials (59-63% versus 46%). The distribution of vascular risk factors in recent clinical trials was comparable to proportions in the registry (hypertension: 77-85% versus 80%; diabetes mellitus: 20-26% versus 27%).

conclusionsThe majority of stroke patients with AF in the clinical setting are considerably older than those included in clinical trials. While the distribution of vascular risk factors in clinical trials corresponds to proportions observed in clinical practice, an overrepresentation of the male sex in clinical trials is evident.

Indexed as

Clinical Trials as TopicAtrial FibrillationHumansRegistriesStroke

Identifiers

PMID26108787
PMCPMC4480890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.